Cardiotoxicity of anticancer treatments: epidemiology, detection, and management
G Curigliano, D Cardinale, S Dent… - CA: a cancer journal …, 2016 - Wiley Online Library
Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …
[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
…, AS Coates, M Colleoni, A Costa, G Curigliano… - Annals of oncology, 2013 - Elsevier
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed
and endorsed substantial new evidence on aspects of the local and regional therapies for …
and endorsed substantial new evidence on aspects of the local and regional therapies for …
[HTML][HTML] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of …
G Curigliano, HJ Burstein, EP Winer, M Gnant… - Annals of …, 2017 - Elsevier
The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed
substantial new evidence on loco-regional and systemic therapies for early breast cancer. …
substantial new evidence on loco-regional and systemic therapies for early breast cancer. …
A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group
…, SJ Hotte, BM Meyers, T Elfiki, G Curigliano… - The …, 2020 - academic.oup.com
The main management strategies for treating cancer patients during the COVID‐19
epidemic include clear communication and education about hand hygiene, infection control …
epidemic include clear communication and education about hand hygiene, infection control …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
[PDF][PDF] HER2-low breast cancer: pathological and clinical landscape
Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …
heterogeneous disease, comprising distinct biologic entities with different prognosis and …
Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial
…, M Bonechi, F De Luca, C Biagioni, G Curigliano… - Clinical cancer …, 2020 - AACR
Purpose: Thymidine kinase 1 (TK1) is downstream to the CDK4/6 pathway, and TK activity (TKa)
measured in blood is a dynamic marker of outcome in patients with advanced breast …
measured in blood is a dynamic marker of outcome in patients with advanced breast …
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
…, J Cortes, JC Soria, G Curigliano - CA: a cancer journal …, 2022 - Wiley Online Library
As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to treat …
tumors by more than their histology has been proposed, and therapies are now tailored to treat …
[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …
…, AS Coates, M Colleoni, G Curigliano… - Annals of oncology, 2015 - Elsevier
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …
new evidence on locoregional and systemic therapies for early breast cancer. Further …
[HTML][HTML] Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
…, H Iwata, E Hamilton, G Curigliano… - … England Journal of …, 2022 - Mass Medical Soc
Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …